CleftGeneDB-Search

Gene: GRB2

Basic information

Tag	Content
Uniprot ID	P62993; P29354; Q14450; Q63057; Q63059;
Entrez ID	2885
Genbank protein ID	AAA58448.1; AAM21073.1; CAG46740.1; CAA44664.1; AAC37549.1; AAH00631.1; AAC72075.1;
Genbank nucleotide ID	NM_002086.4; NM_203506.2;
Ensembl protein ID	ENSP00000339007; ENSP00000496913; ENSP00000376346; ENSP00000376347; ENSP00000317360; ENSP00000376345;
Ensembl nucleotide ID	ENSG00000177885
Gene name	Growth factor receptor-bound protein 2
Gene symbol	GRB2
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Homology search
Reference
Functional description	Adapter protein that provides a critical link between cell surface growth factor receptors and the Ras signaling pathway.
Sequence	MEAIAKYDFK ATADDELSFK RGDILKVLNE ECDQNWYKAE LNGKDGFIPK NYIEMKPHPW 60 FFGKIPRAKA EEMLSKQRHD GAFLIRESES APGDFSLSVK FGNDVQHFKV LRDGAGKYFL 120 WVVKFNSLNE LVDYHRSTSV SRNQQIFLRD IEQVPQQPTY VQALFDFDPQ EDGELGFRRG 180 DFIHVMDNSD PNWWKGACHG QTGMFPRNYV TPVNRNV 217

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
1AZE
1BM2
1BMB
1CJ1
1FHS
1FYR
1GCQ
1GFC
1GFD
1GHU
1GRI
1IO6
1JYQ
1JYR
1JYU
1QG1
1TZE
1X0N
1ZFP
2AOA
2AOB
2H46
2H5K
2HUW
2VVK
2VWF
2W0Z
3C7I
3IMD
3IMJ
3IN7
3IN8
3KFJ
3MXC
3MXY
3N7Y
3N84
3N8M
3OV1
3OVE
3S8L
3S8N
3S8O
3WA4
4P9V
4P9Z
5CDW
6ICG
6ICH
6SDF
1FHS
1GRI
1IO6
1QG1
2VWF
3IMD

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Species	Evidence	Details
1:1 ortholog	GRB2	535298	Q3T0F9		Bos taurus	Prediction	More>>
1:1 ortholog	GRB2	102170356	A0A452ET74		Capra hircus	Prediction	More>>
1:1 ortholog	GRB2	100051866	F7BQS3		Equus caballus	Prediction	More>>
1:1 ortholog	GRB2	2885	P62993		Homo sapiens	Prediction	More>>
1:1 ortholog	Grb2	14784	Q60631	CPO	Mus musculus	Publication	More>>
1:1 ortholog	GRB2	737245	G2HGD2		Pan troglodytes	Prediction	More>>
1:1 ortholog	GRB2	100192436	B6E241		Sus scrofa	Prediction	More>>
1:1 ortholog	GRB2	100342500	G1SR27		Oryctolagus cuniculus	Prediction	More>>
1:1 ortholog	Grb2	81504	P62994		Rattus norvegicus	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
NCI-TCGA novel	p.Ala3Val	missense variant	-	NC_000017.11:g.75393621G>A	NCI-TCGA
rs768682842	p.Ile4Val	missense variant	-	NC_000017.11:g.75393619T>C	ExAC,gnomAD
rs1456069170	p.Ala5Gly	missense variant	-	NC_000017.11:g.75393615G>C	TOPMed
rs1370066638	p.Tyr7Asn	missense variant	-	NC_000017.11:g.75393610A>T	gnomAD
NCI-TCGA novel	p.Tyr7MetPheSerTerUnkUnk	frameshift	-	NC_000017.11:g.75393610A>-	NCI-TCGA
COSM4069545	p.Tyr7Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000017.11:g.75393610A>C	NCI-TCGA Cosmic
rs778762890	p.Lys10Arg	missense variant	-	NC_000017.11:g.75393600T>C	ExAC,gnomAD
rs778762890	p.Lys10Thr	missense variant	-	NC_000017.11:g.75393600T>G	ExAC,gnomAD
NCI-TCGA novel	p.Ala13Val	missense variant	-	NC_000017.11:g.75393591G>A	NCI-TCGA
rs776356926	p.Lys20Arg	missense variant	-	NC_000017.11:g.75393570T>C	gnomAD
rs1264906633	p.Asp23Asn	missense variant	-	NC_000017.11:g.75393562C>T	gnomAD
rs1192603825	p.Ile24Phe	missense variant	-	NC_000017.11:g.75393559T>A	gnomAD
rs149945676	p.Glu30Lys	missense variant	-	NC_000017.11:g.75332788C>T	ESP,TOPMed,gnomAD
rs1325913225	p.Glu30Asp	missense variant	-	NC_000017.11:g.75332786T>G	gnomAD
rs1245281557	p.Glu31Lys	missense variant	-	NC_000017.11:g.75332785C>T	TOPMed
NCI-TCGA novel	p.Cys32Ter	stop gained	-	NC_000017.11:g.75332781_75332782insTGGGATGGATGTCATACTTTTT	NCI-TCGA
NCI-TCGA novel	p.Leu41Ile	missense variant	-	NC_000017.11:g.75332755G>T	NCI-TCGA
rs1474828505	p.Lys50Asn	missense variant	-	NC_000017.11:g.75332726C>G	gnomAD
rs1467933469	p.Tyr52Cys	missense variant	-	NC_000017.11:g.75332721T>C	gnomAD
rs150762903	p.Ile53Thr	missense variant	-	NC_000017.11:g.75332718A>G	ESP,ExAC,gnomAD
rs1368485004	p.Ile53Val	missense variant	-	NC_000017.11:g.75332719T>C	gnomAD
rs1444599555	p.Ile53Met	missense variant	-	NC_000017.11:g.75332717T>C	gnomAD
COSM6082062	p.Ile53Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000017.11:g.75332718A>C	NCI-TCGA Cosmic
rs754676096	p.His58Arg	missense variant	-	NC_000017.11:g.75332703T>C	ExAC,gnomAD
rs55726696	p.Pro59Leu	missense variant	-	NC_000017.11:g.75332700G>A	gnomAD
rs1300552478	p.Phe61Cys	missense variant	-	NC_000017.11:g.75326015A>C	gnomAD
rs746624401	p.Phe62Leu	missense variant	-	NC_000017.11:g.75326011A>C	ExAC,gnomAD
rs1439531650	p.Gly63Ser	missense variant	-	NC_000017.11:g.75326010C>T	gnomAD
rs1441058334	p.Lys64Arg	missense variant	-	NC_000017.11:g.75326006T>C	gnomAD
rs779784380	p.Pro66Ser	missense variant	-	NC_000017.11:g.75326001G>A	ExAC,gnomAD
rs1393017493	p.Met73Val	missense variant	-	NC_000017.11:g.75325980T>C	gnomAD
rs1458191451	p.Arg78Trp	missense variant	-	NC_000017.11:g.75325965G>A	gnomAD
rs749962653	p.Arg78Gln	missense variant	-	NC_000017.11:g.75325964C>T	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.His79Tyr	missense variant	-	NC_000017.11:g.75325962G>A	NCI-TCGA
COSM984354	p.Asp80Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000017.11:g.75325959C>T	NCI-TCGA Cosmic
COSM984353	p.Ala82Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000017.11:g.75325953C>T	NCI-TCGA Cosmic
rs757755769	p.Ile85Thr	missense variant	-	NC_000017.11:g.75325943A>G	ExAC,gnomAD
NCI-TCGA novel	p.Phe95Leu	missense variant	-	NC_000017.11:g.75325912G>C	NCI-TCGA
NCI-TCGA novel	p.Lys100Glu	missense variant	-	NC_000017.11:g.75325899T>C	NCI-TCGA
rs756413472	p.Asp104Asn	missense variant	-	NC_000017.11:g.75321817C>T	ExAC,TOPMed,gnomAD
rs756413472	p.Asp104His	missense variant	-	NC_000017.11:g.75321817C>G	ExAC,TOPMed,gnomAD
rs1216139865	p.Lys109Arg	missense variant	-	NC_000017.11:g.75321801T>C	TOPMed
rs1487234599	p.Arg112Gln	missense variant	-	NC_000017.11:g.75321792C>T	TOPMed
rs759793650	p.Arg112Ter	stop gained	-	NC_000017.11:g.75321793G>A	ExAC,gnomAD
rs1359241313	p.Gly116Arg	missense variant	-	NC_000017.11:g.75321781C>T	gnomAD
COSM984352	p.Lys117Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000017.11:g.75321777T>C	NCI-TCGA Cosmic
rs1287646174	p.Tyr118Phe	missense variant	-	NC_000017.11:g.75321774T>A	gnomAD
rs1430561495	p.Leu120Ile	missense variant	-	NC_000017.11:g.75321769G>T	TOPMed,gnomAD
rs1430561495	p.Leu120Phe	missense variant	-	NC_000017.11:g.75321769G>A	TOPMed,gnomAD
rs1181904019	p.Val122Met	missense variant	-	NC_000017.11:g.75321763C>T	TOPMed
rs776658070	p.Asn126Lys	missense variant	-	NC_000017.11:g.75321749A>T	ExAC,gnomAD
rs147175500	p.Asn126Ser	missense variant	-	NC_000017.11:g.75321750T>C	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Ser127Tyr	missense variant	-	NC_000017.11:g.75321747G>T	NCI-TCGA
rs1433224486	p.Glu130Asp	missense variant	-	NC_000017.11:g.75321737C>A	TOPMed,gnomAD
COSM70974	p.Glu130Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000017.11:g.75321737C>G	NCI-TCGA Cosmic
rs768727425	p.Val132Leu	missense variant	-	NC_000017.11:g.75321733C>A	ExAC,gnomAD
rs760319998	p.Asp133Asn	missense variant	-	NC_000017.11:g.75321730C>T	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Val140Leu	missense variant	-	NC_000017.11:g.75321709C>G	NCI-TCGA
NCI-TCGA novel	p.Arg142Lys	missense variant	-	NC_000017.11:g.75321702C>T	NCI-TCGA
NCI-TCGA novel	p.Asn143Lys	missense variant	-	NC_000017.11:g.75321698G>T	NCI-TCGA
rs1417381613	p.Phe147Leu	missense variant	-	NC_000017.11:g.75321688A>G	gnomAD
rs1185887918	p.Arg149Trp	missense variant	-	NC_000017.11:g.75321682G>A	gnomAD
rs745504425	p.Arg149Gln	missense variant	-	NC_000017.11:g.75321681C>T	ExAC,gnomAD
COSM6147942	p.Ile151Met	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000017.11:g.75321674T>C	NCI-TCGA Cosmic
COSM6082063	p.Val154Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000017.11:g.75321667C>A	NCI-TCGA Cosmic
rs1305943510	p.Gln156His	missense variant	-	NC_000017.11:g.75321659C>G	TOPMed
COSM275366	p.Gln156Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000017.11:g.75321660T>C	NCI-TCGA Cosmic
rs1231922914	p.Pro158Leu	missense variant	-	NC_000017.11:g.75320549G>A	gnomAD
rs1275609833	p.Pro158Ser	missense variant	-	NC_000017.11:g.75320550G>A	TOPMed,gnomAD
COSM6147943	p.Val161Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000017.11:g.75320541C>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Leu164PhePheSerTerUnk	stop gained	-	NC_000017.11:g.75320532_75320533insTCAAGAAGCAATTATTTAAA	NCI-TCGA
NCI-TCGA novel	p.Leu164SerPheSerTerUnkUnk	frameshift	-	NC_000017.11:g.75320533_75320534insAA	NCI-TCGA
NCI-TCGA novel	p.Phe165ThrPheSerTerUnk	stop gained	-	NC_000017.11:g.75320532_75320533insTCAA	NCI-TCGA
rs1371499761	p.Asp168Glu	missense variant	-	NC_000017.11:g.75320518A>C	gnomAD
NCI-TCGA novel	p.Asp168Tyr	missense variant	-	NC_000017.11:g.75320520C>A	NCI-TCGA
rs770576272	p.Gln170Ter	stop gained	-	NC_000017.11:g.75320514G>A	ExAC,gnomAD
NCI-TCGA novel	p.Arg178Ser	missense variant	-	NC_000017.11:g.75320490G>T	NCI-TCGA
rs749010443	p.Arg179Leu	missense variant	-	NC_000017.11:g.75320486C>A	ExAC,TOPMed,gnomAD
rs749010443	p.Arg179Gln	missense variant	-	NC_000017.11:g.75320486C>T	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Phe182Ser	missense variant	-	NC_000017.11:g.75320477A>G	NCI-TCGA
rs772698801	p.His184Arg	missense variant	-	NC_000017.11:g.75320471T>C	ExAC,TOPMed,gnomAD
rs1162708794	p.His184Tyr	missense variant	-	NC_000017.11:g.75320472G>A	gnomAD
rs769240235	p.Met186Ile	missense variant	-	NC_000017.11:g.75320464C>T	ExAC,gnomAD
rs748660687	p.Asn188Asp	missense variant	-	NC_000017.11:g.75320460T>C	ExAC,gnomAD
NCI-TCGA novel	p.Gly196GluPheSerTerUnkUnk	frameshift	-	NC_000017.11:g.75320437T>-	NCI-TCGA
NCI-TCGA novel	p.Gly200Trp	missense variant	-	NC_000017.11:g.75320424C>A	NCI-TCGA
COSM6082064	p.Gln201Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000017.11:g.75320420T>A	NCI-TCGA Cosmic
rs767443992	p.Arg207Cys	missense variant	-	NC_000017.11:g.75320403G>A	TOPMed,gnomAD
rs547957878	p.Arg207His	missense variant	-	NC_000017.11:g.75320402C>T	1000Genomes,ExAC,gnomAD
NCI-TCGA novel	p.Val210Asp	missense variant	-	NC_000017.11:g.75320393A>T	NCI-TCGA
rs758687779	p.Thr211Asn	missense variant	-	NC_000017.11:g.75320390G>T	ExAC,gnomAD
NCI-TCGA novel	p.Pro212Leu	missense variant	-	NC_000017.11:g.75320387G>A	NCI-TCGA
rs765384707	p.Val213Met	missense variant	-	NC_000017.11:g.75320385C>T	ExAC,TOPMed,gnomAD
rs765384707	p.Val213Leu	missense variant	-	NC_000017.11:g.75320385C>A	ExAC,TOPMed,gnomAD
rs1315492591	p.Val213Glu	missense variant	-	NC_000017.11:g.75320384A>T	gnomAD
COSM2978846	p.Val213Ter	frameshift	Variant assessed as Somatic; HIGH impact.	NC_000017.11:g.75320386G>-	NCI-TCGA Cosmic
rs1306575458	p.Arg215Trp	missense variant	-	NC_000017.11:g.75320379G>A	gnomAD
rs371871562	p.Arg215Gln	missense variant	-	NC_000017.11:g.75320378C>T	ESP,ExAC,TOPMed,gnomAD
rs767371260	p.Val217Ile	missense variant	-	NC_000017.11:g.75320373C>T	ExAC,TOPMed,gnomAD

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0002395	Alzheimer's Disease	disease	BEFREE
C0005684	Malignant neoplasm of urinary bladder	disease	BEFREE
C0005695	Bladder Neoplasm	group	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0007134	Renal Cell Carcinoma	disease	BEFREE
C0009402	Colorectal Carcinoma	disease	BEFREE
C0010346	Crohn Disease	disease	BEFREE
C0011860	Diabetes Mellitus, Non-Insulin-Dependent	disease	BEFREE
C0017638	Glioma	disease	BEFREE
C0018213	Graves Disease	disease	BEFREE
C0019196	Hepatitis C	disease	LHGDN
C0023267	Fibroid Tumor	group	LHGDN
C0023418	leukemia	disease	BEFREE
C0023448	Lymphoid leukemia	disease	BEFREE
C0023473	Myeloid Leukemia, Chronic	disease	BEFREE
C0023480	Leukemia, Myelomonocytic, Chronic	disease	BEFREE
C0024141	Lupus Erythematosus, Systemic	disease	GWASDB
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0025149	Medulloblastoma	disease	BEFREE
C0025286	Meningioma	disease	BEFREE
C0026764	Multiple Myeloma	disease	BEFREE
C0027627	Neoplasm Metastasis	phenotype	BEFREE
C0027819	Neuroblastoma	group	BEFREE
C0028860	Oculocerebrorenal Syndrome	disease	BEFREE
C0035309	Retinal Diseases	group	BEFREE
C0036341	Schizophrenia	disease	BEFREE;PSYGENET
C0041296	Tuberculosis	disease	BEFREE
C0042133	Uterine Fibroids	group	BEFREE
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE
C0153676	Secondary malignant neoplasm of lung	disease	BEFREE
C0178874	Tumor Progression	phenotype	BEFREE
C0206180	Ki-1+ Anaplastic Large Cell Lymphoma	disease	BEFREE
C0238462	Medullary carcinoma of thyroid	disease	BEFREE
C0242379	Malignant neoplasm of lung	disease	BEFREE
C0279626	Squamous cell carcinoma of esophagus	disease	BEFREE
C0334579	Anaplastic astrocytoma	disease	BEFREE
C0339467	Proliferative retinopathy	disease	BEFREE
C0339470	Visually threatening diabetic retinopathy	disease	BEFREE
C0345905	Intrahepatic Cholangiocarcinoma	disease	BEFREE
C0424295	Hyperactive behavior	phenotype	BEFREE
C0431375	Classical Lissencephaly	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE
C0684249	Carcinoma of lung	disease	BEFREE
C0686619	Secondary malignant neoplasm of lymph node	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0699885	Carcinoma of bladder	disease	BEFREE
C0700095	Central neuroblastoma	disease	BEFREE
C0853879	Invasive carcinoma of breast	disease	BEFREE
C0919267	ovarian neoplasm	disease	BEFREE
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1458155	Mammary Neoplasms	group	BEFREE
C1512981	Mammary Tumorigenesis	phenotype	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE
C1762616	Meningioma, benign, no ICD-O subtype	disease	BEFREE
C2239176	Liver carcinoma	disease	BEFREE
C2827362	Myeloid and Lymphoid Neoplasms with FGFR1 Rearrangement	disease	BEFREE
C3463824	MYELODYSPLASTIC SYNDROME	group	BEFREE
C4529962	Fatty Liver Disease	disease	BEFREE

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0001784	phosphotyrosine residue binding	IPI
GO:0003723	RNA binding	HDA
GO:0005070	SH3/SH2 adaptor activity	TAS
GO:0005154	epidermal growth factor receptor binding	IPI
GO:0005168	neurotrophin TRKA receptor binding	IPI
GO:0005515	protein binding	IPI
GO:0017124	SH3 domain binding	IDA
GO:0019901	protein kinase binding	IPI
GO:0019903	protein phosphatase binding	IEA
GO:0042802	identical protein binding	IPI
GO:0043560	insulin receptor substrate binding	IPI
GO:0044877	protein-containing complex binding	IEA
GO:0046875	ephrin receptor binding	IPI

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000165	MAPK cascade	TAS
GO:0007173	epidermal growth factor receptor signaling pathway	TAS
GO:0007265	Ras protein signal transduction	TAS
GO:0007267	cell-cell signaling	TAS
GO:0007411	axon guidance	TAS
GO:0007568	aging	IEA
GO:0008286	insulin receptor signaling pathway	IPI
GO:0008286	insulin receptor signaling pathway	TAS
GO:0008543	fibroblast growth factor receptor signaling pathway	TAS
GO:0016032	viral process	IEA
GO:0019221	cytokine-mediated signaling pathway	TAS
GO:0030838	positive regulation of actin filament polymerization	IEA
GO:0031295	T cell costimulation	TAS
GO:0031623	receptor internalization	IMP
GO:0035635	entry of bacterium into host cell	TAS
GO:0035723	interleukin-15-mediated signaling pathway	TAS
GO:0038095	Fc-epsilon receptor signaling pathway	TAS
GO:0038096	Fc-gamma receptor signaling pathway involved in phagocytosis	TAS
GO:0038128	ERBB2 signaling pathway	TAS
GO:0042059	negative regulation of epidermal growth factor receptor signaling pathway	TAS
GO:0042770	signal transduction in response to DNA damage	IMP
GO:0043408	regulation of MAPK cascade	IEA
GO:0046579	positive regulation of Ras protein signal transduction	TAS
GO:0048011	neurotrophin TRK receptor signaling pathway	TAS
GO:0048646	anatomical structure formation involved in morphogenesis	IEA
GO:0050900	leukocyte migration	TAS
GO:0051897	positive regulation of protein kinase B signaling	TAS
GO:0060670	branching involved in labyrinthine layer morphogenesis	IEA
GO:0061024	membrane organization	TAS
GO:0071479	cellular response to ionizing radiation	IMP
GO:2000379	positive regulation of reactive oxygen species metabolic process	IMP

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005634	nucleus	IDA
GO:0005654	nucleoplasm	IDA
GO:0005730	nucleolus	IDA
GO:0005737	cytoplasm	IDA
GO:0005768	endosome	IDA
GO:0005794	Golgi apparatus	IEA
GO:0005829	cytosol	TAS
GO:0005886	plasma membrane	TAS
GO:0005911	cell-cell junction	IEA
GO:0008180	COP9 signalosome	IDA
GO:0012506	vesicle membrane	IEA
GO:0070062	extracellular exosome	HDA
GO:0070436	Grb2-EGFR complex	IDA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-109582	Hemostasis	TAS
R-HSA-109704	PI3K Cascade	TAS
R-HSA-112399	IRS-mediated signalling	TAS
R-HSA-112399	IRS-mediated signalling	IEA
R-HSA-112412	SOS-mediated signalling	TAS
R-HSA-112412	SOS-mediated signalling	IEA
R-HSA-1226099	Signaling by FGFR in disease	TAS
R-HSA-1227986	Signaling by ERBB2	TAS
R-HSA-1227986	Signaling by ERBB2	IEA
R-HSA-1227990	Signaling by ERBB2 in Cancer	TAS
R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	TAS
R-HSA-1236394	Signaling by ERBB4	TAS
R-HSA-1250196	SHC1 events in ERBB2 signaling	IEA
R-HSA-1250347	SHC1 events in ERBB4 signaling	TAS
R-HSA-1257604	PIP3 activates AKT signaling	TAS
R-HSA-1266738	Developmental Biology	TAS
R-HSA-1280215	Cytokine Signaling in Immune system	IEA
R-HSA-1280215	Cytokine Signaling in Immune system	TAS
R-HSA-1280218	Adaptive Immune System	TAS
R-HSA-1280218	Adaptive Immune System	IEA
R-HSA-1295596	Spry regulation of FGF signaling	TAS
R-HSA-1433557	Signaling by SCF-KIT	TAS
R-HSA-1433559	Regulation of KIT signaling	TAS
R-HSA-1500931	Cell-Cell communication	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-162582	Signal Transduction	IEA
R-HSA-1643685	Disease	IEA
R-HSA-1643685	Disease	TAS
R-HSA-1643713	Signaling by EGFR in Cancer	TAS
R-HSA-166520	Signaling by NTRKs	TAS
R-HSA-166520	Signaling by NTRKs	IEA
R-HSA-167044	Signalling to RAS	TAS
R-HSA-167044	Signalling to RAS	IEA
R-HSA-168249	Innate Immune System	TAS
R-HSA-168249	Innate Immune System	IEA
R-HSA-168256	Immune System	TAS
R-HSA-168256	Immune System	IEA
R-HSA-177929	Signaling by EGFR	TAS
R-HSA-179812	GRB2 events in EGFR signaling	TAS
R-HSA-180292	GAB1 signalosome	TAS
R-HSA-180336	SHC1 events in EGFR signaling	TAS
R-HSA-182971	EGFR downregulation	TAS
R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants	TAS
R-HSA-1839124	FGFR1 mutant receptor activation	TAS
R-HSA-186763	Downstream signal transduction	TAS
R-HSA-186797	Signaling by PDGF	TAS
R-HSA-187037	Signaling by NTRK1 (TRKA)	TAS
R-HSA-187037	Signaling by NTRK1 (TRKA)	IEA
R-HSA-187687	Signalling to ERKs	TAS
R-HSA-187687	Signalling to ERKs	IEA
R-HSA-190236	Signaling by FGFR	TAS
R-HSA-194315	Signaling by Rho GTPases	TAS
R-HSA-194315	Signaling by Rho GTPases	IEA
R-HSA-195258	RHO GTPase Effectors	TAS
R-HSA-195258	RHO GTPase Effectors	IEA
R-HSA-1963640	GRB2 events in ERBB2 signaling	TAS
R-HSA-1963640	GRB2 events in ERBB2 signaling	IEA
R-HSA-1963642	PI3K events in ERBB2 signaling	TAS
R-HSA-199418	Negative regulation of the PI3K/AKT network	TAS
R-HSA-199991	Membrane Trafficking	TAS
R-HSA-202733	Cell surface interactions at the vascular wall	TAS
R-HSA-2029480	Fcgamma receptor (FCGR) dependent phagocytosis	TAS
R-HSA-2029480	Fcgamma receptor (FCGR) dependent phagocytosis	IEA
R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation	TAS
R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation	IEA
R-HSA-210993	Tie2 Signaling	TAS
R-HSA-2172127	DAP12 interactions	TAS
R-HSA-2179392	EGFR Transactivation by Gastrin	TAS
R-HSA-2219528	PI3K/AKT Signaling in Cancer	TAS
R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	TAS
R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	TAS
R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	IEA
R-HSA-2424491	DAP12 signaling	TAS
R-HSA-2428924	IGF1R signaling cascade	TAS
R-HSA-2428924	IGF1R signaling cascade	IEA
R-HSA-2428928	IRS-related events triggered by IGF1R	TAS
R-HSA-2428928	IRS-related events triggered by IGF1R	IEA
R-HSA-2428933	SHC-related events triggered by IGF1R	TAS
R-HSA-2428933	SHC-related events triggered by IGF1R	IEA
R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	TAS
R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	IEA
R-HSA-2730905	Role of LAT2/NTAL/LAB on calcium mobilization	TAS
R-HSA-2730905	Role of LAT2/NTAL/LAB on calcium mobilization	IEA
R-HSA-2871796	FCERI mediated MAPK activation	TAS
R-HSA-2871809	FCERI mediated Ca+2 mobilization	IEA
R-HSA-2871809	FCERI mediated Ca+2 mobilization	TAS
R-HSA-354192	Integrin signaling	TAS
R-HSA-354194	GRB2:SOS provides linkage to MAPK signaling for Integrins	TAS
R-HSA-372790	Signaling by GPCR	TAS
R-HSA-375165	NCAM signaling for neurite out-growth	TAS
R-HSA-388396	GPCR downstream signalling	TAS
R-HSA-388841	Costimulation by the CD28 family	TAS
R-HSA-389356	CD28 co-stimulation	TAS
R-HSA-389359	CD28 dependent Vav1 pathway	TAS
R-HSA-391160	Signal regulatory protein family interactions	TAS
R-HSA-416476	G alpha (q) signalling events	TAS
R-HSA-422475	Axon guidance	TAS
R-HSA-449147	Signaling by Interleukins	TAS
R-HSA-449147	Signaling by Interleukins	IEA
R-HSA-451927	Interleukin-2 family signaling	TAS
R-HSA-451927	Interleukin-2 family signaling	IEA
R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling	TAS
R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling	IEA
R-HSA-5637810	Constitutive Signaling by EGFRvIII	TAS
R-HSA-5637812	Signaling by EGFRvIII in Cancer	TAS
R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	TAS
R-HSA-5653656	Vesicle-mediated transport	TAS
R-HSA-5654687	Downstream signaling of activated FGFR1	TAS
R-HSA-5654688	SHC-mediated cascade:FGFR1	TAS
R-HSA-5654689	PI-3K cascade:FGFR1	TAS
R-HSA-5654693	FRS-mediated FGFR1 signaling	TAS
R-HSA-5654695	PI-3K cascade:FGFR2	TAS
R-HSA-5654696	Downstream signaling of activated FGFR2	TAS
R-HSA-5654699	SHC-mediated cascade:FGFR2	TAS
R-HSA-5654700	FRS-mediated FGFR2 signaling	TAS
R-HSA-5654704	SHC-mediated cascade:FGFR3	TAS
R-HSA-5654706	FRS-mediated FGFR3 signaling	TAS
R-HSA-5654708	Downstream signaling of activated FGFR3	TAS
R-HSA-5654710	PI-3K cascade:FGFR3	TAS
R-HSA-5654712	FRS-mediated FGFR4 signaling	TAS
R-HSA-5654716	Downstream signaling of activated FGFR4	TAS
R-HSA-5654719	SHC-mediated cascade:FGFR4	TAS
R-HSA-5654720	PI-3K cascade:FGFR4	TAS
R-HSA-5654726	Negative regulation of FGFR1 signaling	TAS
R-HSA-5654727	Negative regulation of FGFR2 signaling	TAS
R-HSA-5654732	Negative regulation of FGFR3 signaling	TAS
R-HSA-5654733	Negative regulation of FGFR4 signaling	TAS
R-HSA-5654736	Signaling by FGFR1	TAS
R-HSA-5654738	Signaling by FGFR2	TAS
R-HSA-5654741	Signaling by FGFR3	TAS
R-HSA-5654743	Signaling by FGFR4	TAS
R-HSA-5655253	Signaling by FGFR2 in disease	TAS
R-HSA-5655291	Signaling by FGFR4 in disease	TAS
R-HSA-5655302	Signaling by FGFR1 in disease	TAS
R-HSA-5655332	Signaling by FGFR3 in disease	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5663205	Infectious disease	IEA
R-HSA-5663205	Infectious disease	TAS
R-HSA-5663213	RHO GTPases Activate WASPs and WAVEs	TAS
R-HSA-5663213	RHO GTPases Activate WASPs and WAVEs	IEA
R-HSA-5673001	RAF/MAP kinase cascade	TAS
R-HSA-5683057	MAPK family signaling cascades	TAS
R-HSA-5684996	MAPK1/MAPK3 signaling	TAS
R-HSA-6806834	Signaling by MET	TAS
R-HSA-6807004	Negative regulation of MET activity	TAS
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	TAS
R-HSA-74749	Signal attenuation	TAS
R-HSA-74751	Insulin receptor signalling cascade	TAS
R-HSA-74751	Insulin receptor signalling cascade	IEA
R-HSA-74752	Signaling by Insulin receptor	TAS
R-HSA-74752	Signaling by Insulin receptor	IEA
R-HSA-76002	Platelet activation, signaling and aggregation	TAS
R-HSA-76009	Platelet Aggregation (Plug Formation)	TAS
R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	TAS
R-HSA-8851805	MET activates RAS signaling	TAS
R-HSA-8851907	MET activates PI3K/AKT signaling	TAS
R-HSA-8853334	Signaling by FGFR3 fusions in cancer	TAS
R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	TAS
R-HSA-8853659	RET signaling	TAS
R-HSA-8856825	Cargo recognition for clathrin-mediated endocytosis	TAS
R-HSA-8856828	Clathrin-mediated endocytosis	TAS
R-HSA-8865999	MET activates PTPN11	TAS
R-HSA-8875360	InlB-mediated entry of Listeria monocytogenes into host cell	IEA
R-HSA-8875360	InlB-mediated entry of Listeria monocytogenes into host cell	TAS
R-HSA-8875555	MET activates RAP1 and RAC1	TAS
R-HSA-8875656	MET receptor recycling	TAS
R-HSA-8875878	MET promotes cell motility	TAS
R-HSA-8876384	Listeria monocytogenes entry into host cells	IEA
R-HSA-8876384	Listeria monocytogenes entry into host cells	TAS
R-HSA-8983432	Interleukin-15 signaling	IEA
R-HSA-8983432	Interleukin-15 signaling	TAS
R-HSA-9006115	Signaling by NTRK2 (TRKB)	TAS
R-HSA-9006115	Signaling by NTRK2 (TRKB)	IEA
R-HSA-9006335	Signaling by Erythropoietin	IEA
R-HSA-9006335	Signaling by Erythropoietin	TAS
R-HSA-9006925	Intracellular signaling by second messengers	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	IEA
R-HSA-9026519	Activated NTRK2 signals through RAS	IEA
R-HSA-9027284	Erythropoietin activates RAS	IEA
R-HSA-9027284	Erythropoietin activates RAS	TAS
R-HSA-9028335	Activated NTRK2 signals through PI3K	IEA
R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	TAS
R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	IEA
R-HSA-9034015	Signaling by NTRK3 (TRKC)	IEA
R-HSA-9034864	Activated NTRK3 signals through RAS	IEA
R-HSA-912526	Interleukin receptor SHC signaling	TAS
R-HSA-912631	Regulation of signaling by CBL	TAS
R-HSA-912631	Regulation of signaling by CBL	IEA
R-HSA-9607240	FLT3 Signaling	IEA
R-HSA-9607240	FLT3 Signaling	TAS
R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	TAS
R-HSA-9645135	STAT5 Activation	IEA
R-HSA-9664565	Signaling by ERBB2 KD Mutants	TAS
R-HSA-983695	Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	TAS
R-HSA-983695	Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	IEA
R-HSA-983705	Signaling by the B Cell Receptor (BCR)	TAS
R-HSA-983705	Signaling by the B Cell Receptor (BCR)	IEA

Drugs and compounds information

ID	Drug Name	Action	PubMed
D015647	2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine	2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of GRB2 protein	25852303
C496492	abrine	abrine results in decreased expression of GRB2 mRNA	31054353
C496492	abrine	abrine results in decreased expression of GRB2 protein	31054353
D000082	Acetaminophen	Acetaminophen affects the expression of GRB2 mRNA	17562736
D000082	Acetaminophen	Acetaminophen affects the expression of GRB2 mRNA	16701773
D016604	Aflatoxin B1	Aflatoxin B1 results in increased methylation of GRB2 intron	30157460
C029753	aflatoxin B2	aflatoxin B2 results in decreased methylation of GRB2 intron	30157460
C031143	AICA ribonucleotide	GRB2 protein affects the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein]	11978788
C038491	allyl sulfide	allyl sulfide results in decreased expression of GRB2 protein	21695758
D000517	alpha-Chlorohydrin	alpha-Chlorohydrin analog results in decreased expression of GRB2 protein	26597043
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of GRB2 mRNA	16483693
D000643	Ammonium Chloride	Ammonium Chloride results in decreased expression of GRB2 protein	16483693
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of GRB2 mRNA	24449571
C025657	arsenic acid	arsenic acid promotes the reaction [SHC1 protein binds to GRB2 protein]	14674888
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of GRB2 protein	25419056
D000077237	Arsenic Trioxide	Arsenic Trioxide results in increased expression of GRB2 mRNA	20458559
C015001	arsenite	arsenite promotes the reaction [SHC1 protein binds to GRB2 protein]	14674888
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite affects the expression of GRB2 mRNA	17331233
C547126	AZM551248	AZM551248 results in increased expression of GRB2 mRNA	22323515
D001397	Azoxymethane	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRB2 mRNA	29950665
D001564	Benzo(a)pyrene	Benzo(a)pyrene affects the methylation of GRB2 intron	30157460
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of GRB2 protein	21467743
C026487	benzo(e)pyrene	benzo(e)pyrene results in decreased methylation of GRB2 intron	30157460
C006780	bisphenol A	bisphenol A affects the expression of GRB2 mRNA	21786754
C006780	bisphenol A	bisphenol A results in increased expression of GRB2 protein	30615907
C006780	bisphenol A	ESR1 protein affects the reaction [bisphenol A results in increased expression of GRB2 protein]	30615907
C006780	bisphenol A	bisphenol A results in increased expression of GRB2 mRNA	25181051
C022777	bufalin	bufalin results in decreased expression of GRB2 protein	23949904
D019328	Buthionine Sulfoximine	Buthionine Sulfoximine results in decreased expression of GRB2 mRNA	15878706
D002104	Cadmium	Cadmium results in increased expression of GRB2 protein	14499349
D002117	Calcitriol	Calcitriol results in increased expression of GRB2 mRNA	15951637
C054133	casticin	casticin results in decreased expression of GRB2 protein	28444820
C026690	cerous chloride	cerous chloride affects the expression of GRB2 mRNA	23139204
D004390	Chlorpyrifos	Chlorpyrifos results in increased expression of GRB2 mRNA	27737797
C043561	chrysin	chrysin results in decreased expression of GRB2 protein	30578657
D002994	Clofibrate	Clofibrate results in decreased expression of GRB2 mRNA	23811191
C018021	cobaltous chloride	cobaltous chloride results in increased expression of GRB2 mRNA	19376846
D003042	Cocaine	Cocaine results in increased expression of GRB2 protein	25100957
D019327	Copper Sulfate	Copper Sulfate results in increased expression of GRB2 mRNA	19549813
D003474	Curcumin	Curcumin analog results in decreased expression of GRB2 mRNA	26409325
C017160	cypermethrin	cypermethrin results in decreased expression of GRB2 mRNA	27704156
D003634	DDT	DDT promotes the reaction [GRB2 protein binds to SOS1 protein]	9070211
C010902	decabromobiphenyl ether	decabromobiphenyl ether results in increased expression of GRB2 mRNA	23640034
D003907	Dexamethasone	Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to GRB2 protein]]	10807665
D003907	Dexamethasone	Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to GRB2 protein]]]	10807665
D016264	Dextran Sulfate	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRB2 mRNA	29950665
C028009	diallyl disulfide	diallyl disulfide affects the expression of GRB2 protein	21695758
C028009	diallyl disulfide	diallyl disulfide results in decreased expression of GRB2 protein	21695758
D004041	Dietary Fats	Dietary Fats results in decreased expression of GRB2 mRNA	18042831
D004147	Dioxins	Dioxins affects the expression of GRB2 mRNA	20463971
D004791	Enzyme Inhibitors	[Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of GRB2 protein	23301498
D004958	Estradiol	Estradiol results in increased expression of GRB2 mRNA	23094148
D004958	Estradiol	IGF1R mutant form inhibits the reaction [Estradiol results in increased expression of GRB2 mRNA]	23094148
D004958	Estradiol	[Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of GRB2 mRNA	22465879
D004958	Estradiol	[Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of GRB2 protein	22465879
D000431	Ethanol	Ethanol affects the splicing of GRB2 mRNA	30319688
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of GRB2 mRNA	17942748
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of GRB2 mRNA	17942748
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of GRB2 mRNA	23129252
D017313	Fenretinide	Fenretinide results in increased expression of GRB2 protein	15059897
D018120	Finasteride	Finasteride results in increased expression of GRB2 mRNA	24136188
D005419	Flavonoids	Flavonoids results in increased expression of GRB2 mRNA	18035473
D005707	Gallic Acid	Gallic Acid results in decreased expression of GRB2 protein	22387266
D019833	Genistein	Genistein results in decreased expression of GRB2 mRNA	16705744
D019833	Genistein	Genistein results in increased expression of GRB2 mRNA	20884965
D005839	Gentamicins	Gentamicins results in increased expression of GRB2 mRNA	22061828
D006861	Hydrogen Peroxide	Hydrogen Peroxide affects the expression of GRB2 mRNA	21179406
C031927	hydroquinone	hydroquinone affects the expression of GRB2 protein	20021034
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GRB2 mRNA	25613284
D000077289	Letrozole	Letrozole results in increased expression of GRB2 protein	15967659
D008344	Maneb	[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA	23963992
D008344	Maneb	Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]	23963992
D008344	Maneb	Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]	23963992
D008550	Melatonin	Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]	23963992
D008610	Menthol	Menthol results in decreased expression of GRB2 mRNA	26760959
D008694	Methamphetamine	Methamphetamine affects the expression of GRB2 protein	17904249
D008701	Methapyrilene	Methapyrilene results in decreased methylation of GRB2 intron	30157460
D008713	Methimazole	Methimazole results in increased expression of GRB2 mRNA	17403546
D008770	Methylnitrosourea	[Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of GRB2 mRNA	22465879
D008770	Methylnitrosourea	[Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of GRB2 protein	22465879
D052998	Microcystins	Microcystins results in decreased expression of GRB2 protein	22430071
D015735	Mifepristone	Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to GRB2 protein]]]	10807665
D009532	Nickel	Nickel results in increased expression of GRB2 mRNA	24768652; 25583101;
D009569	Nitric Oxide	Nitric Oxide deficiency results in decreased expression of GRB2 mRNA	15878706
C010615	Nonidet P-40	Nonidet P-40 results in decreased expression of GRB2 mRNA	26552463
D010042	Ouabain	Ouabain results in decreased expression of GRB2 protein	28795476
C029341	oxophenylarsine	[oxophenylarsine results in decreased phosphorylation of PLCG1 protein] inhibits the reaction [PLCG1 protein binds to GRB2 protein]	9281317
D000073878	Palm Oil	Palm Oil results in decreased expression of GRB2 mRNA	18042831
D010269	Paraquat	[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA	23963992
D010269	Paraquat	Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]	23963992
D010269	Paraquat	Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]	23963992
C494474	perchlorate	perchlorate results in increased expression of GRB2 mRNA	17403546
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in decreased expression of GRB2 mRNA	19162173
D010578	Petroleum	Petroleum affects the expression of GRB2 mRNA	25208076
C006253	pirinixic acid	pirinixic acid results in decreased expression of GRB2 mRNA	23811191
D010936	Plant Extracts	Plant Extracts results in decreased expression of GRB2 protein	23955962
D011285	Pregnenolone Carbonitrile	Pregnenolone Carbonitrile results in increased expression of GRB2 mRNA	28903501
D011374	Progesterone	[Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of GRB2 mRNA	22465879
D011374	Progesterone	[Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of GRB2 protein	22465879
C045950	propiconazole	propiconazole results in decreased expression of GRB2 mRNA	21278054
D011441	Propylthiouracil	Propylthiouracil results in decreased expression of GRB2 mRNA	17403546
D011794	Quercetin	Quercetin results in decreased expression of GRB2 protein	23645742
D011794	Quercetin	Quercetin results in increased expression of GRB2 mRNA	27514524
D000077185	Resveratrol	Resveratrol promotes the reaction [[ITGAV protein binds to ITGB3 protein] which affects the localization of GRB2 protein]	21467134
D000077185	Resveratrol	Resveratrol results in decreased expression of GRB2 mRNA	12002526
D012715	Sesame Oil	Sesame Oil results in increased expression of GRB2 mRNA	29191790
D012838	Silymarin	Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]	23963992
C017947	sodium arsenite	sodium arsenite results in increased expression of GRB2 mRNA	12016162
C017947	sodium arsenite	sodium arsenite promotes the reaction [SHC1 protein modified form binds to GRB2 protein]	9710602
C017947	sodium arsenite	[sodium arsenite results in increased phosphorylation of SHC1 protein] promotes the reaction [SHC1 protein modified form binds to GRB2 protein]	9710602
D018038	Sodium Selenite	Sodium Selenite results in decreased expression of GRB2 mRNA	16705456
D018038	Sodium Selenite	Sodium Selenite results in increased expression of GRB2 mRNA	18175754
D000077157	Sorafenib	Sorafenib results in decreased expression of GRB2 mRNA	26409325
D013467	Sulindac	Sulindac results in increased expression of GRB2 mRNA	24136188
D013605	T-2 Toxin	T-2 Toxin results in decreased expression of GRB2 mRNA	31299295
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in increased expression of GRB2 mRNA	15336504
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of GRB2 mRNA	21570461
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of GRB2 mRNA	17942748
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of GRB2 mRNA	19465110; 22666406;
D013749	Tetrachlorodibenzodioxin	CBL protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [GRB2 protein binds to SOS1 protein]]	9918770
D013749	Tetrachlorodibenzodioxin	CBL protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [SHC1 protein binds to [GRB2 protein binds to SOS1 protein]]]	9918770
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of GRB2 mRNA	22298810
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [GRB2 protein binds to SOS1 protein]	9918770
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [SHC1 protein binds to [GRB2 protein binds to SOS1 protein]]	9918770
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GRB2 mRNA	25613284
C009438	tetrandrine	tetrandrine results in decreased expression of GRB2 protein	30549224
D013893	Thiram	Thiram results in decreased expression of GRB2 mRNA	20530235
C016151	tinuvin	tinuvin analog results in decreased expression of GRB2 mRNA	30315675
C009495	titanium dioxide	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRB2 mRNA	29950665
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the expression of GRB2 protein	30291989
D014118	Toxins, Biological	Toxins, Biological affects the expression of GRB2 mRNA	19682533
C046488	trimethyltin	trimethyltin results in increased expression of GRB2 mRNA	20833246
C001899	triptolide	triptolide results in decreased expression of GRB2 protein	26420756
D014501	Uranium	Uranium affects the expression of GRB2 mRNA	15672453
C005460	uranyl acetate	uranyl acetate affects the expression of GRB2 mRNA	15672453
D014635	Valproic Acid	Valproic Acid results in increased expression of GRB2 mRNA	23179753
D001335	Vehicle Emissions	Vehicle Emissions results in decreased methylation of GRB2 gene	25560391
D001335	Vehicle Emissions	Vehicle Emissions results in decreased expression of GRB2 mRNA	19165385
D014874	Water Pollutants, Chemical	Water Pollutants, Chemical affects the expression of GRB2 mRNA	25208076

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0007	Acetylation
KW-0025	Alternative splicing
KW-0963	Cytoplasm
KW-0903	Direct protein sequencing
KW-0967	Endosome
KW-0333	Golgi apparatus
KW-0945	Host-virus interaction
KW-0539	Nucleus
KW-0597	Phosphoprotein
KW-1185	Reference proteome
KW-0677	Repeat
KW-0727	SH2 domain
KW-0728	SH3 domain

Interpro

InterPro ID	InterPro Term
IPR030219	Grb2
IPR035643	GRB2_C_SH3
IPR035641	GRB2_N_SH3
IPR000980	SH2
IPR036860	SH2_dom_sf
IPR036028	SH3-like_dom_sf
IPR001452	SH3_domain

PROSITE

PROSITE ID	PROSITE Term
PS50001	SH2
PS50002	SH3

Pfam

Pfam ID	Pfam Term
PF00017	SH2
PF00018	SH3_1

Gene: GRB2

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction